Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for GVHD Prophylaxis in Aggressive NHL
NCT00785330Phase 2Completed
- Sponsor
- Institut für anwendungsorientierte Forschung und klinische Studien
- Start
- Apr 2004
- Primary completion
- Mar 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in graft-versus-host disease (GVHD) (2 arms), sponsored by Institut für anwendungsorientierte Forschung und klinische Studien. Primary endpoint: Rate of Acute Graft-Versus-Host Disease Grade II-IV at 1 year. Started Apr 2004; status: completed.
02
Drugs
rituximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00785330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00785330.